Natera, Inc. (NASDAQ:NTRA) Shares Sold by Bleakley Financial Group LLC

Bleakley Financial Group LLC decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 14.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,898 shares of the medical research company’s stock after selling 317 shares during the period. Bleakley Financial Group LLC’s holdings in Natera were worth $241,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Itau Unibanco Holding S.A. bought a new position in shares of Natera in the second quarter valued at approximately $28,000. Quarry LP boosted its stake in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. GAMMA Investing LLC boosted its stake in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares in the last quarter. Tobam acquired a new position in shares of Natera during the 2nd quarter valued at $74,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Natera in the 1st quarter worth $83,000. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Canaccord Genuity Group lifted their target price on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. The Goldman Sachs Group boosted their target price on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. BTIG Research raised their target price on shares of Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. TD Cowen upped their price target on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Leerink Partners increased their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average price target of $124.44.

Natera Trading Down 1.1 %

Shares of NASDAQ NTRA opened at $118.65 on Thursday. The firm has a market capitalization of $14.57 billion, a PE ratio of -38.03 and a beta of 1.53. Natera, Inc. has a one year low of $36.90 and a one year high of $133.54. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average price of $123.43 and a two-hundred day moving average price of $111.03.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same period in the previous year, the firm posted ($0.97) earnings per share. The firm’s revenue was up 58.1% on a year-over-year basis. As a group, analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 496 shares of Natera stock in a transaction on Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total transaction of $59,068.64. Following the completion of the sale, the chief financial officer now owns 74,314 shares of the company’s stock, valued at approximately $8,850,054.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Michael Burkes Brophy sold 496 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total transaction of $59,068.64. Following the completion of the sale, the chief financial officer now directly owns 74,314 shares of the company’s stock, valued at $8,850,054.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jonathan Sheena sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the sale, the insider now directly owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 49,458 shares of company stock valued at $5,924,920. 7.60% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.